Last reviewed · How we verify
Patients treated with Esketamine — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Patients treated with Esketamine (Patients treated with Esketamine) — Neuronetics.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Patients treated with Esketamine TARGET | Patients treated with Esketamine | Neuronetics | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Patients treated with Esketamine CI watch — RSS
- Patients treated with Esketamine CI watch — Atom
- Patients treated with Esketamine CI watch — JSON
- Patients treated with Esketamine alone — RSS
Cite this brief
Drug Landscape (2026). Patients treated with Esketamine — Competitive Intelligence Brief. https://druglandscape.com/ci/patients-treated-with-esketamine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab